Elaine Chen, Allison DeAngelis, and Adam Feuerstein

BioTech

The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children

What do drugmakers think about RFK Jr.? Why has it been so hard to bring gene therapies to market? And what tacos did Adam have

Elaine Chen, Allison DeAngelis, and Adam Feuerstein December 12, 2024

BioTech

Genentech’s cancer pivot, Pfizer’s sickle cell withdrawal, and a new schizophrenia drug

Why are Genentech’s cancer researchers concerned about the direction of the company? What led Pfizer to pull its sickle cell drug off global markets? And

Elaine Chen, Allison DeAngelis, and Adam Feuerstein September 26, 2024

BioTech

Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target

How effective is Summit Therapeutics’ lung cancer immunotherapy? Why are obesity drugmakers turning back to a two-decade-old idea? And how long will Elaine last as

Elaine Chen, Allison DeAngelis, and Adam Feuerstein September 5, 2024

BioTech

JD Vance’s biotech ties, Cassava resignations, and insulin shortages

What relation does JD Vance have with Vivek Ramaswamy? Do pharma companies have a moral responsibility to patients? And what does $300 champagne taste like?

Elaine Chen, Allison DeAngelis, and Adam Feuerstein July 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Elaine Chen, Allison DeAngelis, and Adam Feuerstein

The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children

Genentech’s cancer pivot, Pfizer’s sickle cell withdrawal, and a new schizophrenia drug

Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target

JD Vance’s biotech ties, Cassava resignations, and insulin shortages

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe